Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia
Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia
Recruiting · NCT06034561 · Registry updated 2025-05-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2025-05-16 | NCT06034561 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Instituto do Cancer do Estado de São Paulo | 26 |
| Libbs Farmacêutica LTDA | 5 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Instituto do Cancer do Estado de Sao Paulo | São Paulo | Brazil | 3 |